ArticleTranslational lung cancer research2025
Immune checkpoint inhibitors have limited efficacy in
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Low-dose radiotherapy as an immunomodulator in cancer: dose-specific mechanisms and hybrid high-dose/low-dose strategies.Biomarker research · 2026Review
- Two-year treatment-free sustained remission after chemo-immunotherapy in a 52-year-old male with recurrentTranslational lung cancer research · 2026Article
- Clinical phenotype identification based on inflammation-nutrition-coagulation biomarkers in advanced non-small cell lung cancer.Frontiers in nutrition · 2026Article
- Clinicopathological and Genomic Analysis ofCancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: From October 2020 to May 2025, 95 patients with SD-NSCLC, confirmed by immunohistochemistry (IHC) at Tianjin Medical University Cancer Institute & Hospital, were included for analysis. Validation and molecular mechanism exploration were conducted using the TCGA database. Disease-free survival (DFS) and progression-free survival (PFS) were the primary endpoints of the study. The disease control rate (DCR) was a secondary endpoint. Results: In stage IV SD-NSCLC patients, no significant difference in PFS was observed between those treated with ICIs and non-ICIs (P=0.60). However, the median PFS (mPFS) differences were significant between Conclusions:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.